Mainz Biomed and TestDNA Drive CRC Innovation at the 10th Gdańsk Gastroenterology Symposium

January 19, 2024

https://www.globenewswire.com/news-release/2024/01/11/2807886/0/en/Mainz-Biomed-and-TestDNA-Drive-CRC-Innovation-at-the-10th-Gda%C5%84sk-Gastroenterology-Symposium.html

BERKELEY, Calif. and MAINZ, Germany, Jan. 11, 2024 (GLOBE NEWSWIRE) — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in early cancer detection, re-affirms its collaboration with TestDNA at the upcoming 10th Gdańsk Gastroenterology Symposium on January 12th–13th, 2024. The companies joined forces to advance innovative colorectal cancer (CRC) detection in Poland and to increase treatment options as well as survival rates through early detection.

Read more at globenewswire.com

Related news for (MYNZ)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.